8,976 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Bar Harbor Wealth Management

Bar Harbor Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 8,976 shares of the biopharmaceutical company’s stock, valued at approximately $4,712,000.

Several other hedge funds have also modified their holdings of REGN. Nuveen LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $343,764,000. Pacer Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after acquiring an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock worth $305,311,000 after acquiring an additional 303,785 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after buying an additional 174,056 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after buying an additional 121,545 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Jefferies Financial Group increased their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a report on Friday, August 1st. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $817.67.

Regeneron Pharmaceuticals Trading Down 3.3%

Regeneron Pharmaceuticals stock opened at $563.86 on Thursday. The stock has a 50-day moving average of $573.34 and a two-hundred day moving average of $566.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,024.36. The stock has a market cap of $59.76 billion, a PE ratio of 14.21, a price-to-earnings-growth ratio of 1.86 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. During the same period last year, the business posted $11.56 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.